Innovative pharmaceutical companies remain in the top 15 leaders of the Ukrainian pharmaceutical market due to budget procurement.
According to the presentation of SMD analytical company, presented during the joint seminar with Arzinger law firm “Participation in budget procurement brings multinational pharmaceutical companies good results”.
In particular, budget purchases account for 68% of sales in Ukraine of Roche, 54% of Boehringer and 46% of Pfizer. At the same time, Yuria Pharm is the leader among domestic pharmaceutical companies in budget purchases, budget purchases from which account for 68% of total sales.
At the same time, the reimbursement program “Affordable Medicines” provides a significant volume of sales to such companies as Kyiv Vitamin Plant (KVZ), Astra Zeneca, KRKA and TEVA.
In general, Pharmak with a 6.1% share, Darnitsa (4.6%) and Yuria-Pharm (4.1%) remained the leaders of the pharmaceutical market in terms of sales in 2024.
Among foreign pharmaceutical companies, the leaders were Sanofi and Teva, which at the end of 2023 held 2.7% of the market each, as well as AstraZeneca with a 2.1% share.
